Oculis (European Biotech Acquisition) ^{Priced, Nasdaq: OCS}

European Biotech Acquisition is a newly organized blank check company. LSP, an affiliate of our sponsor, is one of Europe’s largest and most experienced healthcare investment firms. With an investment track record of more than 30 years, LSP’s partners are dedicated to nurturing and growing healthcare businesses that have the potential to have a positive impact on society. With a committed team of highly experienced investment professionals spread across its offices in Amsterdam, Munich and Boston, LSP aims to invest in companies that have highly innovative products, with a strong scientific and clinical rationale, and significant breakthrough potential. While we may pursue an initial business combination opportunity in any business, industry, sector or geographical location, we intend to capitalize on the ability of our management team to identify promising opportunities in the life sciences industry in Europe. LSP has invested in hundreds of private and public life sciences companies making it one of the largest life sciences investment firms in Europe. LSP has built its reputation amongst industry entrepreneurs and academics as a leading life sciences investor due to its investment expertise, value-additive capabilities and the high level of engagement of the team.